ACLY and CKD: A Mendelian Randomization Analysis.

ABSTRACT:

Introduction

Adenosine triphosphate-citrate lyase (ACLY) inhibition is a therapeutic strategy under investigation for atherosclerotic cardiovascular disease, nonalcoholic steatohepatitis, and metabolic syndrome. Mouse models suggest that ACLY inhibition could reduce inflammation and kidney fibrosis. Genetic analysis of ACLY in chronic kidney disease (CKD) has not been performed.

Methods

We constructed a genetic instrument by selecting variants associated with ACLY expression in the expression quantitative trait loci genetics consortium (eQTLGen) from blood samples from 31,684 participants. In a 2-sample Mendelian randomization analysis, we evaluated the effect of genetically predicted ACLY expression on the risk of CKD, estimated glomerular filtration rate (eGF

SUBMITTER: Mohammadi-Shemirani P 

PROVIDER: S-EPMC9263230 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature